Rimegepant idiki molecule inhibitor yecalcitoningene-related peptide (CGRP) receptor inovhara chiito cheCGRP, ine simba vasodilator inotendwa kuita basa mumigraine misoro.Rimegepant inotenderwa kurapwa kweacute migraine kurwisa.Mumiedzo yekiriniki, rimegepant yaiwanzoremerwa nezviitiko zvisingawanzoitiki zvenguva pfupi serum aminotransferase kukwidziridzwa panguva yekurapa uye pasina zviitiko zvakashumwa zvekukuvara kwechiropa.

Rimegepant mupikisi wemuromo weCGRP receptor yakagadzirwa neBiohaven Pharmaceuticals.Yakagamuchira mvumo yeFDA muna Kukadzi 27, 2020 yeacute kurapwa migraine musoro.Kunyange zvazvo vanopesana nevakawanda veCGRP uye mutevedzeri wayo vakabvumirwa kurapa migraine (eg [erenumab], [fremanezumab], [galcanezumab]), rimegepant uye [ubrogepant] ndidzo chete nhengo dzemhuri ye "gepants" yemishonga yasara mukuvandudzwa, uye ndivo chete vanopikisa CGRP vane oral bioavailability.Iyo yazvino chiyero chemigraine therapy inosanganisira kubvisa nhumbu ne "triptans", senge [sumatriptan], asi mishonga iyi inopesana nevarwere vane cerebrovascular uye chirwere chemwoyo chisati chavapo nekuda kwevasoconstrictive properties.Kupikisa kweCGRP nzira kwave kunokwezva chinangwa chemigraine therapy sezvo, kusiyana ne triptans, nemuromo CGRP vanopikisa havana kucherechedzwa vasoconstrictive properties uye saka yakachengeteka kushandiswa kune varwere vane contraindications kune yakajairwa kurapwa.

Rimegepant ariCalcitoninGene-yakabatana Peptide Receptor Antagonist.Iyo nzira yekuita kwerimegepant yakaita seaCalcitoninGene-yakabatana Peptide Receptor Antagonist.